Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra ...

AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global ...

Gubra has been actively involved in obesity research, previously collaborating with Boehringer Ingelheim on multiple programmes. In 2021, the two companies signed a deal to co-develop four obesity ...

Last November, Gubra announced encouraging preliminary Phase 1 data showing a single dose of GUB014925 led to 3% weight loss that was sustained for the six weeks of the trial. The placebo group ...

(RTTNews) - AbbVie (ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a potential long-acting amylin analog for the treatment of obesity. AbbVie will lead development and ...

HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders ...

Introduction & Market Context. Gubra AS (NASDAQ COPENHAGEN:GUBRA) presented its first quarter 2025 results on May 9, highlighting a transformative partnership with AbbVie (NYSE: ABBV) and progress in ...

Founded in 2008, Gubra is a highly specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. In this interview, CEO Henrik ...

Gubra, which provides pre-clinical contract research and peptide-based drug discovery services, will be eligible to receive certain royalties on global net sales of the drug, called GUB014295.

Gubra will receive an upfront payment of $350 million, with the potential to receive an additional $1.875 billion pending development and sales milestones. 1 "We are excited to partner with AbbVie ...

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra’s long-term strategy focuses on leveraging its expertise in peptide-based drug discovery and development, with a particular emphasis on obesity and metabolic disorders.